Home » Healthcare » Chronic Venous Occlusions Treatment Market
Chronic Venous Occlusions Treatment Market By Treatment Type (Minimally invasive, Pharmacological treatment, Surgical treatment, Compression therapy, Others); By Indication Type (Chronic deep vein thrombosis, Varicose veins, Deep vein insufficiency, Others); By Product Type (Devices, Therapeutics / drugs, Compression / supportive equipment); By End User (Hospitals, Ambulatory surgical centers, Specialty clinics, Home care settings, Others); By Region – Growth, Share, Opportunities & Competitive Analysis, 2025 – 2032
The global Chronic Venous Occlusions Treatment Market size was estimated at USD 7,419 million in 2025 and is expected to reach USD 9,942 million by 2032, growing at a CAGR of 4.27% from 2025 to 2032. Demand is being propelled by the steady shift toward minimally invasive venous interventions that can restore flow, reduce post-thrombotic symptoms, and shorten recovery time versus open procedures. Rising diagnosis rates for chronic deep vein thrombosis and deep venous outflow obstruction, alongside broader access to duplex imaging and specialist referral pathways, is improving treatment conversion. Product innovation across venous stents, thrombectomy systems, and supportive compression solutions is also expanding the treatable patient pool and encouraging protocol standardization across hospitals and outpatient settings.
The market is projected to expand from USD 7,419 million (2025) to USD 9,942 million (2032), reflecting a 4.27% CAGR (2025–2032).
Minimally invasive approaches accounted for the largest share of 34.8% in 2025, supported by outpatient feasibility and faster recovery pathways.
Deep vein insufficiency represented 27.1% in 2025, indicating the continued burden of chronic venous dysfunction driving sustained intervention demand.
North America contributed 38.6% of 2025 revenue, reflecting high procedure adoption and established vascular care infrastructure.
Asia Pacific reached 22.7% in 2025, reflecting expanding specialist capacity and increasing diagnosis and treatment penetration.
Segment Analysis
The market shows a clear preference shift toward procedure-led care models, where minimally invasive interventions are increasingly used to address symptomatic obstruction and chronic venous dysfunction. Patient outcomes are influenced by earlier diagnosis, better anatomical assessment, and broader use of device-based therapy to restore venous patency. Pharmacological treatment and compression therapy remain foundational for symptom control and long-term management, but are increasingly positioned as complementary to interventions rather than standalone pathways for complex occlusions.
Across indications, chronic deep vein thrombosis and deep vein insufficiency continue to drive the heaviest clinical demand due to recurrent symptoms, mobility limitations, and long-term complications. Hospitals remain pivotal for advanced interventions that require imaging, trained interventional teams, and post-procedure monitoring. However, ambulatory and specialty settings are gaining momentum as case selection improves and more procedures transition to outpatient pathways.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
Minimally invasive accounted for the largest share of 34.8% in 2025. The segment leads due to faster recovery, reduced inpatient burden, and the ability to treat complex lesions using catheter-based techniques. Increasing clinician familiarity with venous stenting, thrombectomy, and endovenous adjuncts supports broader adoption. Procedure standardization and improved imaging guidance continue to strengthen physician confidence and referral conversion.
By Indication Type Insights
Deep vein insufficiency accounted for the largest share of 27.1% in 2025. High prevalence of chronic venous dysfunction and persistent symptom recurrence sustain ongoing demand for evaluation and treatment. Better diagnostic workups and structured referral pathways are enabling earlier identification of venous outflow problems. As device-based interventions become more accessible, clinical preference is shifting toward solutions that improve functional outcomes and reduce long-term complications.
By Product Type Insights
The product landscape is shaped by the interplay of devices, therapeutics/drugs, and compression/supportive equipment, with purchasing decisions influenced by clinical protocols and total episode-of-care costs. Devices are central to procedural workflows, while drugs support anticoagulation, symptom control, and adjunct care in select patients. Compression and supportive equipment remain essential for long-term management and recurrence prevention, and product design improvements that enhance patient adherence can lift utilization across both hospital and home settings.
By End User Insights
Hospitals remain the primary treatment setting for complex venous occlusion cases because they concentrate advanced imaging, specialist teams, and post-procedure monitoring capacity. Ambulatory surgical centers are expanding their role as minimally invasive workflows become more standardized and case selection improves. Specialty clinics are strengthening referral networks and improving continuity of care through follow-up and long-term management. Home care settings remain important for compression adherence and chronic symptom management, especially in long-duration disease pathways.
Expansion of minimally invasive venous intervention pathways
Minimally invasive procedures are increasingly preferred because they reduce recovery time and help limit hospital stays for eligible patients. Catheter-based approaches enable targeted therapy while maintaining procedural flexibility across lesion complexity. Standardization of interventional workflows and broader physician training improve adoption consistency across care settings. As health systems seek better throughput and predictable outcomes, procedure-led pathways are reinforcing demand for both devices and adjunct therapies.
For instance, BD’s 22-center VERNACULAR study of the Venovo venous stent enrolled 170 patients, achieved 100% technical success and 98.8% procedural success, and reported 88.6% 12-month primary patency with no stent migration or fractures through 36 months.
Rising chronic venous disease burden and earlier diagnosis
Population aging, sedentary lifestyles, and comorbidity prevalence contribute to growing chronic venous disease burden. Greater access to vascular imaging and structured referral pathways supports earlier identification of symptomatic venous obstruction. Earlier diagnosis increases the likelihood of intervention before complications progress, improving treatment conversion. This dynamic supports sustained volumes across interventions, drugs, and supportive equipment as more patients enter managed care pathways.
For instance, ThinkSono Guidance demonstrated 100% sensitivity and 95% specificity for proximal DVT diagnosis in one study, while a larger multicentre UK Oxford trial reported 85% sensitivity, 73% specificity, and 97% negative predictive value; its pivotal DVT GUARD study also set a target that at least 75% of scans acquired by non-specialists should be adequate for interpretation.
Technology innovation across devices and supportive care
Innovation in venous stents, thrombectomy systems, imaging guidance, and supportive products expands the treatable patient pool. Improved deliverability and procedural control increase physician confidence and can shorten procedure time. Device improvements also enhance long-term patency and symptom relief, strengthening clinical preference for interventional management. Supportive product enhancements that improve usability can raise adherence and reinforce long-term disease management effectiveness.
Shift toward outpatient care models and efficiency-focused delivery
Outpatient care expansion supports growth in ambulatory and specialty settings as more patients are treated through efficient pathways. Health systems prioritize cost-effective treatment approaches that reduce inpatient resource utilization. Better patient stratification and standardized protocols improve suitability for outpatient procedures. This shift increases the importance of integrated care models that combine intervention, pharmacological management, and compression adherence across the full treatment journey.
Reimbursement variability and uneven access to specialist care can slow adoption of advanced venous interventions in several geographies. Even where clinical demand is high, coverage differences across payers and care settings can create inconsistent procedure volumes. Patient adherence to conservative management, especially compression therapy, is also a persistent barrier that can reduce symptom control and worsen recurrence risk. These constraints can limit real-world outcomes and complicate long-term care planning for providers.
Clinical complexity and patient heterogeneity create operational challenges across diagnosis, treatment selection, and longitudinal monitoring. Chronic Venous Occlusions Treatment often require individualized planning based on anatomy, prior thrombosis history, and comorbidities, increasing pathway variability. Provider training requirements and skill gaps can restrict uptake in lower-resource facilities. In addition, post-procedure follow-up needs can strain capacity and affect continuity of care where referral networks are fragmented.
For instance, in Medtronic’s ABRE clinical study, the Abre venous self-expanding stent delivered 81.6% primary patency and 89.3% freedom from clinically driven target lesion revascularization through 36 months, even though 47.5% of enrolled patients had post-thrombotic syndrome and 35.8% of those patients presented with complete venous occlusion.
Chronic Venous Occlusions Treatment Market Trends and Opportunities
Device-led innovation and protocol standardization are creating opportunities for broader adoption of minimally invasive therapy across a larger set of patient profiles. As care teams gain experience, confidence in procedural outcomes improves, and institutions are more likely to invest in dedicated venous programs. Integrated pathways that combine intervention with structured follow-up and conservative therapy can improve outcomes and reduce recurrence. This creates space for value-based care models that emphasize long-term symptom control and functional improvement.
For instance, Boston Scientific’s VICI VENOUS STENT® System demonstrated an 84.0% primary patency rate at 12 months in the VIRTUS trial, with 98.8% of patients free from major adverse events at 30 days, enabling centers to standardize iliac vein reconstruction protocols with predictable outcomes.
Outpatient expansion and the growth of specialty vascular clinics are opening new commercial channels for device makers, supportive therapy providers, and service partners. As workflows shift toward predictable recovery pathways, procedure volumes can scale outside tertiary hospitals. This favors solutions that improve throughput, simplify training, and enhance patient adherence. Digital follow-up tools and patient education programs also represent opportunities to strengthen continuity of care and improve long-term management.
Regional Insights
North America
North America accounted for 38.6% of market revenue in 2025, supported by strong interventional adoption and well-established vascular care delivery. Hospitals continue to handle complex cases that require advanced imaging and specialist teams, while outpatient and specialty settings expand as minimally invasive workflows become more standardized. Demand is reinforced by higher diagnosis rates and structured referral pathways that improve treatment conversion. Innovation in venous devices and supportive therapy solutions also supports broader protocol adoption.
Europe
Europe represented 24.9% in 2025, shaped by mature healthcare systems and growing emphasis on efficient care pathways. Increasing outpatient orientation and structured chronic disease management approaches support steady procedural volumes. Demand is supported by rising chronic venous disease burden and the availability of trained specialists in major markets. Expansion of dedicated venous programs and standardized follow-up models can strengthen long-term outcomes and sustain adoption.
Asia Pacific
Asia Pacific contributed 22.7% in 2025, driven by improving access to vascular diagnostics and expanding interventional capability in key countries. Growth is supported by aging demographics, rising lifestyle risk factors, and increasing awareness of chronic venous symptoms. As specialist capacity expands, more patients are likely to transition from conservative management to intervention where clinically appropriate. Market growth also benefits from investments in hospital infrastructure and referral network development.
Latin America
Latin America held 8.4% in 2025, with demand concentrated in larger healthcare markets and tertiary care hubs. Uneven access to specialist care and advanced devices can constrain procedure penetration outside major cities. Even so, improving diagnostic availability and gradual expansion of minimally invasive care pathways support steady adoption. Greater training and stronger referral networks can accelerate treatment conversion and expand outpatient channel development.
Middle East & Africa
Middle East & Africa accounted for 5.4% in 2025, influenced by varied healthcare capacity across countries. Demand is strongest in markets with advanced tertiary care infrastructure and growing investment in vascular services. Expansion of specialist training and access to modern devices can raise procedural adoption over time. Strengthening follow-up pathways and improving adherence to supportive therapy can also improve long-term disease management outcomes.
Competitive Landscape
Competition centers on expanding minimally invasive portfolios, improving device performance and deliverability, and strengthening provider training and service support. Companies differentiate through clinical evidence generation, hospital contracting, and portfolio breadth spanning devices, imaging support, and supportive management. Partnerships with care providers and distribution scale are important for improving access, especially as outpatient care settings expand. Product usability and adherence-focused supportive solutions remain key for long-duration management pathways.
Medtronic focuses on strengthening its vascular solutions positioning by aligning device innovation with clinically scalable workflows across hospital and outpatient environments. The company’s approach emphasizes procedural reliability, integration with established interventional practices, and support for standardized care pathways. Participation across broader vascular segments also supports bundled value propositions for large provider networks. These factors can strengthen adoption where health systems prioritize predictable outcomes and throughput.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In June 2024, Royal Philips announced the first implant of its Duo Venous Stent System following U.S. FDA premarket approval, marking a notable product launch for the treatment of symptomatic venous outflow obstruction in patients with chronic venous insufficiency. The company stated that the device was developed by Vesper Medical, a wholly owned subsidiary of Philips, and is being marketed under the Philips brand.
In October 2025, InterVene received U.S. FDA 510(k) clearance for the Recana Thrombectomy Catheter System and announced the launch of the platform for treating venous in-stent restenosis and native vessel obstructions and occlusions. The company described Recana as the first fully integrated thrombectomy system designed specifically to address these difficult venous obstructions, making it a meaningful product update in this market.
Report Scope
Report Attribute
Details
Market size value in 2025
USD 7419 million
Revenue forecast in 2032
USD 9942 million
Growth rate (CAGR)
4.27% (2025–2032)
Base year
2025
Forecast period
2026-2032
Quantitative units
USD million
Segments covered
By Treatment Type Outlook: Minimally invasive, Pharmacological treatment, Surgical treatment, Compression therapy, Others; By Indication Type Outlook: Chronic deep vein thrombosis, Varicose veins, Deep vein insufficiency, Others; By Product Type Outlook: Devices, Therapeutics / drugs, Compression / supportive equipment; By End User Outlook: Hospitals, Ambulatory surgical centers, Specialty clinics, Home care settings, Others
Regional scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Key companies profiled
Medtronic; BD (Becton, Dickinson and Company); Boston Scientific; Cook Medical; Terumo Corporation; Cordis; Merit Medical Systems; Inari Medical; W. L. Gore & Associates; Philips; 3M; SIGVARIS Group / medi
No. of Pages
328
Segmentation
By Treatment Type
Minimally invasive
Pharmacological treatment
Surgical treatment
Compression therapy
Others
By Indication Type
Chronic deep vein thrombosis
Varicose veins
Deep vein insufficiency
Others
By Product Type
Devices
Therapeutics / drugs
Compression / supportive equipment
By End User
Hospitals
Ambulatory surgical centers
Specialty clinics
Home care settings
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Table of Contents
Introduction
1.1. Report Description
1.2. Purpose of the Report
1.3. USP & Key Offerings
1.4. Key Benefits for Stakeholders
1.5. Target Audience
1.6. Report Scope
1.7. Regional Scope
Scope and Methodology
2.1. Objectives of the Study
2.2. Stakeholders
2.3. Data Sources
2.3.1. Primary Sources
2.3.2. Secondary Sources
2.4. Market Estimation
2.4.1. Bottom-Up Approach
2.4.2. Top-Down Approach
2.5. Forecasting Methodology
Executive Summary
Introduction
4.1. Overview
4.2. Key Industry Trends
Global Chronic Venous Occlusions Treatment Market
5.1. Market Overview
5.2. Market Performance
5.3. Impact of COVID-19
5.4. Market Forecast
Market Breakup by Region
10.1. North America
10.1.1. United States
10.1.1.1. Market Trends
10.1.1.2. Market Forecast
10.1.2. Canada
10.1.2.1. Market Trends
10.1.2.2. Market Forecast
10.2. Asia-Pacific
10.2.1. China
10.2.2. Japan
10.2.3. India
10.2.4. South Korea
10.2.5. Australia
10.2.6. Indonesia
10.2.7. Others
10.3. Europe
10.3.1. Germany
10.3.2. France
10.3.3. United Kingdom
10.3.4. Italy
10.3.5. Spain
10.3.6. Russia
10.3.7. Others
10.4. Latin America
10.4.1. Brazil
10.4.2. Mexico
10.4.3. Others
10.5. Middle East and Africa
10.5.1. Market Trends
10.5.2. Market Breakup by Country
10.5.3. Market Forecast
Porters Five Forces Analysis
13.1. Overview
13.2. Bargaining Power of Buyers
13.3. Bargaining Power of Suppliers
13.4. Degree of Competition
13.5. Threat of New Entrants
13.6. Threat of Substitutes
Price Analysis
Competitive Landscape
15.1. Market Structure
15.2. Key Players
15.3. Profiles of Key Players
15.3.1. Medtronic
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. Financials
15.3.1.4. SWOT Analysis
15.3.2. BD (Becton, Dickinson and Company)
15.3.3. Boston Scientific
15.3.4. Cook Medical
15.3.5. Terumo Corporation
15.3.6. Cordis
15.3.7. Merit Medical Systems
15.3.8. Inari Medical
15.3.9. W. L. Gore & Associates
15.3.10. Philips
15.3.11. 3M
15.3.12. SIGVARIS Group
Research Methodology
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions
What is the market size and forecast for the Chronic Venous Occlusions Treatment Market?
The market was valued at USD 7,419 million in 2025 and is projected to reach USD 9,942 million by 2032. Growth is supported by expanded diagnosis and greater adoption of minimally invasive care pathways.
What is the CAGR of the Chronic Venous Occlusions Treatment Market?
The market is expected to grow at a 4.27% CAGR during 2025–2032. This reflects steady expansion in intervention volumes and chronic disease management needs.
What is the largest segment in 2025?
By treatment type, minimally invasive approaches are the largest segment at 34.8% in 2025. The segment leads due to faster recovery and outpatient feasibility.
What are the key growth factors for this market?
Key factors include rising chronic venous disease burden, earlier diagnosis, and increasing use of minimally invasive interventions. Technology innovation in devices and supportive therapy is also improving care pathways.
Who are the leading companies in the market?
Key companies include Medtronic, BD, Boston Scientific, Cook Medical, Terumo, Cordis, Merit Medical Systems, Inari Medical, W. L. Gore & Associates, Philips, 3M, and SIGVARIS Group. Competition focuses on portfolio depth, clinical evidence, and channel reach.
Which region leads the market in 2025?
North America leads with 38.6% revenue share in 2025. The region benefits from strong specialist capacity and higher adoption of advanced interventions.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
Cosmetic Surgery And Procedure Market size was valued USD 83070 million in 2024 and is anticipated to reach USD 179236.8 million by 2032, at a CAGR of 10.09% during the forecast period.
Cannula Market size was valued USD 190 million in 2024 and is anticipated to reach USD 342.3 million by 2032, at a CAGR of 7.64% during the forecast period.
Corneal Topographers Market size was valued USD 793 million in 2024 and is anticipated to reach USD 1172.21 million by 2032, at a CAGR of 5% during the forecast period.
Dog Vaccine Market size was valued USD 2.8 billion in 2024 and is anticipated to reach USD 5.83 billion by 2032, at a CAGR of 9.6% during the forecast period.
The oral syringes market was valued at USD 1709 million in 2024 and is projected to reach USD 2758.39 million by 2032, growing at a CAGR of 6.17% during the forecast period.
The Oscillating Positive Expiratory Pressure (OPEP) Devices market was valued at USD 879 million in 2024 and is expected to reach USD 1,829.26 million by 2032, growing at a CAGR of 9.6% during the forecast period.
The dental tourism market was valued at USD 12469 million in 2024 and is projected to reach USD 54367.89 million by 2032, growing at a CAGR of 20.21% during the forecast period.
The glucose monitoring devices market was valued at USD 13,154 million in 2024. The market is projected to reach USD 20,080.85 million by 2032. Growth is expected at a CAGR of 5.43% during the forecast period.
The medical physics market was valued at USD 5,289 million in 2024. The market is projected to reach USD 8,557.3 million by 2032. Growth is expected at a CAGR of 6.2% during the forecast period.
Nanoparticle Formulation Market size was valued USD 8589 million in 2024 and is anticipated to reach USD 16863.73 million by 2032, at a CAGR of 8.8% during the forecast period.
Bile Duct Cancer Treatment Market size was valued USD 3880 million in 2024 and is anticipated to reach USD 7235.44 million by 2032, at a CAGR of 8.1% during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$5999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
